<DOC>
	<DOCNO>NCT01769456</DOCNO>
	<brief_summary>Approximately 100 HIV-uninfected YMSM high risk acquire HIV infection , age 15 17 inclusive enrol across participate Adolescent Medicine Trial Units ( AMTUs ) . Assignment behavioral intervention , include Many Men , Many Voices ( 3MV ) Personalized Cognitive Counseling ( PCC ) , occur level site . Subjects first complete behavioral intervention offer respective site provide open label emtricitabine ( FTC ) /tenofovir ( TDF ) ( Truvada® ) pre-exposure prophylaxis ( PrEP ) . Behavioral biomedical data collect baseline 0 , 4 , 8 , 12 , 24 , 36 48 week . Any subject becomes HIV infect course study discontinue study agent follow additional 24 week study visit HIV infection confirm . Those subject meet specific bone renal criterion Week 48 visit 24-Week HIV Seropositive visit follow additional 48 week Extension Phase closely monitor longer-term outcome potential concern .</brief_summary>
	<brief_title>An Open Label Demonstration Project Phase II Safety Study Pre-Exposure Prophylaxis Use Among 15 17 Year Old Young Men Who Have Sex With Men ( YMSM )</brief_title>
	<detailed_description>The aim study obtain additional data safety FTC/TDF ( Truvada® ) evaluate acceptability , pattern use , rate adherence , measured level drug exposure YMSM provide open label FTC/TDF ( Truvada® ) information regard safety efficacy PrEP prior study . The study also examine pattern sexual risk behavior among high-risk HIV-1 uninfected YMSM U.S. provide open label FTC/TDF ( Truvada® ) PrEP . The study also explore feasibility acceptability implement two different type efficacious risk reduction intervention prior provision PrEP - 3MV PCC . The inclusion behavioral intervention project address ethical responsibility provide least minimum risk reduction education subject give high HIV risk study population , also build behavioral skill assist subject reduce risk take PrEP . Furthermore , study evaluate process protocol implementation well understand best implement PrEP research program practice adolescent medicine site , include evaluation consent procedure acceptability/feasibility allow youth minor consent participation HIV prevention intervention , extent allowable local law regulation , allow youth minor participation clinical trial without require disclosure sexual orientation risk behavior parent guardian .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Willing able provide write informed consent ; Male gender birth ; Age 15 year 0 day 17 year 364 day , inclusive , time sign informed consent ; Self report evidence high risk acquire HIV infection include least one following : At least one episode unprotected anal intercourse HIVinfected male partner male partner unknown HIV status last 6 month ; Anal intercourse 3 male sex partner last 6 month ; Exchange money , gift , shelter , drug anal sex male partner last 6 month ; Sex male partner sexually transmit infection ( STI ) last 6 month screen ; Sexual partner HIVinfected man condom consistently use last 6 month ; At least one episode anal intercourse condom break slip last 6 month ; Tests HIV antibody negative time screen ; Willing provide locator information study staff ; Willing take PrEP ; Willing participate behavioral intervention ; Reports intention relocate AMTU study area course study ; Does job obligation would require long absence AMTU study area ( great 4 week time ) . Appears visibly distraught presence active serious psychiatric symptom ( e.g. , active hallucination , suicidal , homicidal , exhibit violent behavior ) time consent ; Intoxicated influence alcohol drug time consent ; Any significant uncontrolled , active chronic disease process , judgment site investigator , would make participation study inappropriate . ( Appropriately manage condition , like wellcontrolled diabetes , would preclude enrollment ; site encourage contact Adolescent Medicine Trials Network HIV/AIDS Interventions ( ATN ) 113 Protocol Team difficulty make judgment . ) ; History bone fracture explain trauma ; Acute chronic hepatitis B infection indicate positive hepatitis B surface antigen ( sAg ) test time screen ; Confirmed renal dysfunction ( Creatinine Clearance ( CrCl ) &lt; 75 ml/min calculate base bedside Schwartz formula : Glomerular filtration rate ( GFR ) = ( 0.413 x ( height centimeter ) ) / ( serum creatinine mg/dl ) ) , serum creatinine &gt; upper limit normal ( ULN ) , history renal parenchymal disease presence one kidney time screen ; Confirmed ≥ Grade 2 hypophosphatemia time screen ; Confirmed ≥ Grade 2 hematologic system abnormality ( White Blood Count ( WBC ) , Absolute Neutrophil Count ( ANC ) , hemoglobin , platelet ) time screen ; Confirmed ≥ Grade 2 hepatobiliary system abnormality ( Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , bilirubin ) time screen ; Confirmed proteinuria indicate urine dipstick result ≥ 1+ time screening , regardless urine protein creatinine ratio ( UP/C ) ; UP/C &gt; 0.37 g/g time screening , regardless urine dipstick protein result ; Confirmed normoglycemic glucosuria indicate urine dipstick result ≥ 1+ presence normal serum glucose ( &lt; 120 mg/dL ) time screen ; A confirm Grade ≥ 3 toxicity screening evaluation ; Known allergy/sensitivity study agent component ; Concurrent participation HIV vaccine study investigational drug study , include oral topical PrEP ( microbicide ) study ; Use disallow medication ; Inability understand spoken English .</criteria>
	<gender>Male</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV , PrEP , FTC/TDF , Truvada</keyword>
</DOC>